Search

Your search keyword '"Ulasi, Ifeoma I."' showing total 27 results
Start Over Author "Ulasi, Ifeoma I." Search Limiters Available in Library Collection
27 results on '"Ulasi, Ifeoma I."'

2. Cardiovascular Risk Factor Burden and Association With CKD in Ghana and Nigeria

Author

Olanrewaju, Timothy O., Osafo, Charlotte, Raji, Yemi R., Mamven, Manmak, Ajayi, Samuel, Ilori, Titilayo O., Arogundade, Fatiu A., Ulasi, Ifeoma I., Gbadegesin, Rasheed, Parekh, Rulan S., Tayo, Bamidele, Adeyemo, Adebowale A., Adedoyin, Olanrewaju T., Chijioke, Adindu A., Bewaji, Clement, Grobbee, Diederick E., Blankestijn, Peter J., Klipstein-Grobusch, Kerstin, Salako, Babatunde L., Adu, Dwomoa, and Ojo, Akinlolu O.

Published
2023
Full Text
View/download PDF

4. Cardiovascular Risk Factor Burden and Association With CKD in Ghana and Nigeria

Author

Global Health team 1, Global Health, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, MS Nefrologie, Olanrewaju, Timothy O., Osafo, Charlotte, Raji, Yemi R., Mamven, Manmak, Ajayi, Samuel, Ilori, Titilayo O., Arogundade, Fatiu A., Ulasi, Ifeoma I., Gbadegesin, Rasheed, Parekh, Rulan S., Tayo, Bamidele, Adeyemo, Adebowale A., Adedoyin, Olanrewaju T., Chijioke, Adindu A., Bewaji, Clement, Grobbee, Diederick E., Blankestijn, Peter J., Klipstein-Grobusch, Kerstin, Salako, Babatunde L., Adu, Dwomoa, Ojo, Akinlolu O., Global Health team 1, Global Health, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, MS Nefrologie, Olanrewaju, Timothy O., Osafo, Charlotte, Raji, Yemi R., Mamven, Manmak, Ajayi, Samuel, Ilori, Titilayo O., Arogundade, Fatiu A., Ulasi, Ifeoma I., Gbadegesin, Rasheed, Parekh, Rulan S., Tayo, Bamidele, Adeyemo, Adebowale A., Adedoyin, Olanrewaju T., Chijioke, Adindu A., Bewaji, Clement, Grobbee, Diederick E., Blankestijn, Peter J., Klipstein-Grobusch, Kerstin, Salako, Babatunde L., Adu, Dwomoa, and Ojo, Akinlolu O.

Published
2023

5. Cardiovascular Risk Factor Burden and Association With CKD in Ghana and Nigeria

Author

Olanrewaju, Timothy O., primary, Osafo, Charlotte, additional, Raji, Yemi R., additional, Mamven, Manmak, additional, Ajayi, Samuel, additional, Ilori, Titilayo O., additional, Arogundade, Fatiu A., additional, Ulasi, Ifeoma I., additional, Gbadegesin, Rasheed, additional, Parekh, Rulan S., additional, Tayo, Bamidele, additional, Adeyemo, Adebowale A., additional, Adedoyin, Olanrewaju T., additional, Chijioke, Adindu A., additional, Bewaji, Clement, additional, Grobbee, Diederick E., additional, Blankestijn, Peter J., additional, Klipstein-Grobusch, Kerstin, additional, Salako, Babatunde L., additional, Adu, Dwomoa, additional, and Ojo, Akinlolu O., additional

Published
2022
Full Text
View/download PDF

6. Systematic review of international studies evaluating MDRD and CKD-EPI estimated glomerular filtration rate (eGFR) equations in Black adults

Author

Umeukeje, Ebele M., primary, Koonce, Taneya Y., additional, Kusnoor, Sheila V., additional, Ulasi, Ifeoma I., additional, Kostelanetz, Sophia, additional, Williams, Annette M., additional, Blasingame, Mallory N., additional, Epelbaum, Marcia I., additional, Giuse, Dario A., additional, Apple, Annie N., additional, Kaur, Karampreet, additional, González Peña, Tavia, additional, Barry, Danika, additional, Eisenstein, Leo G., additional, Nutt, Cameron T., additional, and Giuse, Nunzia B., additional

Published
2022
Full Text
View/download PDF

10. Chronic Kidney Disease Burden in Low-Resource Settings: Regional Perspectives

Author

Ulasi, Ifeoma I., Awobusuyi, Olugbenga, Nayak, Saurabh, Ramachandran, Raja, Musso, Carlos G., Depine, Santos A., Aroca-Martínez, Gustavo, Uzoamaka Solarin, Adaobi, Macaulay, Onuigbo, Luyckx, Valerie A., and Ijoma, Chinwuba K.

Subjects
Burden of chronic kidney disease, Low- and middle-income countries, Health systems, Nephrology, Low-resource setting
Abstract

The burden of chronic kidney disease (CKD) has increased exponentially worldwide but more so in low- and middle-income countries. Specific risk factors in these regions expose their populations to an increased risk of CKD, such as genetic risk with APOL1 among populations of West African heritage or farmers with CKD of unknown etiology that spans various countries across several continents to immigrant/indigenous populations in both low- and high-income countries. Low- and middle-income economies also have the double burden of communicable and noncommunicable diseases, both contributing to the high prevalence of CKD. The economies are characterized by low health expenditure, sparse or nonexistent health insurance and welfare programs, and predominant out-of-pocket spending for medical care. This review highlights the challenges in populations with CKD from low-resource settings globally and explores how health systems can help ameliorate the CKD burden.

Published
2022

11. International consensus definitions of clinical trial outcomes for kidney failure: 2020

Author

Anand, Shuchi, Argent, Nicholas, Babak, Elena, Banerjee, Debasish, Barratt, Jonathan, Bello, Aminu K., Bernardo, Angelito A., Blais, Jaime, Canovatchel, William, Caskey, Fergus J., Coresh, Josef, de Boer, Ian H., Eckardt, Kai-Uwe, Evans, Rhys DR., Feldman, Harold I., Fogo, Agnes B., Gudmundsdottir, Hrefna, Hamano, Takayuki, Harris, David C.H., Hauske, Sibylle J., Haynes, Richard, Herzog, Charles A., Hiemstra, Thomas, Idorn, Thomas, Inker, Lesley, Ishida, Julie H., Johnson, David W., Jones-Burton, Charlotte, Joseph, Amer, Koitka-Weber, Audrey, Kretzler, Matthias, Lawatscheck, Robert, Liew, Adrian, Moist, Louise, Naicker, Saraladevi, Nakashima, Reiko, Patel, Uptal, Filho, Roberto Pecoits, Rose, Jennifer B., Rosenberg, Noah L., Sinsakul, Marvin, Smoyer, William E., Sola, Laura, Sood, Amy R., Stengel, Benedicte, Taal, Maarten W., Tanaka, Mototsugu, Tonelli, Marcello, Tong, Allison, Toto, Robert, Trask, Michele, Ulasi, Ifeoma I., Wanner, Christoph, Wheeler, David C., Wolthers, Benjamin O., Wright, Harold M., Yamada, Yoshihisa, Zakharova, Elena, Levin, Adeera, Agarwal, Rajiv, Herrington, William G., Heerspink, Hiddo L., Mann, Johannes F.E., Shahinfar, Shahnaz, Tuttle, Katherine R., Donner, Jo-Ann, Jha, Vivekanand, Nangaku, Masaomi, de Zeeuw, Dick, Jardine, Meg J., Mahaffey, Kenneth W., Thompson, Aliza M., Beaucage, Mary, Chong, Kate, Roberts, Glenda V., Sunwold, Duane, Vorster, Hans, Warren, Madeleine, Damster, Sandrine, Malik, Charu, and Perkovic, Vlado

Published
2020
Full Text
View/download PDF

12. International consensus definitions of clinical trial outcomes for kidney failure: 2020

Author

Levin, Adeera, primary, Agarwal, Rajiv, additional, Herrington, William G., additional, Heerspink, Hiddo L., additional, Mann, Johannes F.E., additional, Shahinfar, Shahnaz, additional, Tuttle, Katherine R., additional, Donner, Jo-Ann, additional, Jha, Vivekanand, additional, Nangaku, Masaomi, additional, de Zeeuw, Dick, additional, Jardine, Meg J., additional, Mahaffey, Kenneth W., additional, Thompson, Aliza M., additional, Beaucage, Mary, additional, Chong, Kate, additional, Roberts, Glenda V., additional, Sunwold, Duane, additional, Vorster, Hans, additional, Warren, Madeleine, additional, Damster, Sandrine, additional, Malik, Charu, additional, Perkovic, Vlado, additional, Anand, Shuchi, additional, Argent, Nicholas, additional, Babak, Elena, additional, Banerjee, Debasish, additional, Barratt, Jonathan, additional, Bello, Aminu K., additional, Bernardo, Angelito A., additional, Blais, Jaime, additional, Canovatchel, William, additional, Caskey, Fergus J., additional, Coresh, Josef, additional, de Boer, Ian H., additional, Eckardt, Kai-Uwe, additional, Evans, Rhys DR., additional, Feldman, Harold I., additional, Fogo, Agnes B., additional, Gudmundsdottir, Hrefna, additional, Hamano, Takayuki, additional, Harris, David C.H., additional, Hauske, Sibylle J., additional, Haynes, Richard, additional, Herzog, Charles A., additional, Hiemstra, Thomas, additional, Idorn, Thomas, additional, Inker, Lesley, additional, Ishida, Julie H., additional, Johnson, David W., additional, Jones-Burton, Charlotte, additional, Joseph, Amer, additional, Koitka-Weber, Audrey, additional, Kretzler, Matthias, additional, Lawatscheck, Robert, additional, Liew, Adrian, additional, Moist, Louise, additional, Naicker, Saraladevi, additional, Nakashima, Reiko, additional, Patel, Uptal, additional, Filho, Roberto Pecoits, additional, Rose, Jennifer B., additional, Rosenberg, Noah L., additional, Sinsakul, Marvin, additional, Smoyer, William E., additional, Sola, Laura, additional, Sood, Amy R., additional, Stengel, Benedicte, additional, Taal, Maarten W., additional, Tanaka, Mototsugu, additional, Tonelli, Marcello, additional, Tong, Allison, additional, Toto, Robert, additional, Trask, Michele, additional, Ulasi, Ifeoma I., additional, Wanner, Christoph, additional, Wheeler, David C., additional, Wolthers, Benjamin O., additional, Wright, Harold M., additional, Yamada, Yoshihisa, additional, and Zakharova, Elena, additional

Published
2020
Full Text
View/download PDF

13. Progress report on the first sub-Saharan Africa trial of newer versus older antihypertensive drugs in native black patients

Author

Odili Augustine N, Ezeala-Adikaibe Birinus, Ndiaye Mouhamadou B, Anisiuba Benedict C, Kamdem Marius M, Ijoma Chinwuba K, Kaptue Joseph, Boombhi Hilaire J, Kolo Philip M, Shu Elvis N, Thijs Lutgarde, Staessen Jan A, Omotoso Babatunde A, Kingue Samuel, Ba Serigne A, Lemogoum Daniel, M’Buyamba-Kabangu Jean-René, and Ulasi Ifeoma I

Subjects
Antihypertensive therapy, Health policy and outcome research, Randomized clinical trial, Special populations, Medicine (General), R5-920
Abstract

Abstract Background The epidemic surge in hypertension in sub-Saharan Africa is not matched by clinical trials of antihypertensive agents in Black patients recruited in this area of the world. We mounted the Newer versus Older Antihypertensive agents in African Hypertensive patients (NOAAH) trial to compare, in native African patients, a single-pill combination of newer drugs, not involving a diuretic, with a combination of older drugs including a diuretic. Methods Patients aged 30 to 69 years with uncomplicated hypertension (140 to 179/90 to 109 mmHg) and ≤2 associated risk factors are eligible. After a four week run-in period off treatment, 180 patients have to be randomized to once daily bisoprolol/hydrochlorothiazide 5/6.25 mg (R) or amlodipine/valsartan 5/160 mg (E). To attain blood pressure Results At the time of writing of this progress report, of 206 patients enrolled in the run-in period, 140 had been randomized. At randomization, the R and E groups were similar (P ≥ 0.11) with respect to mean age (50.7 years), body mass index (28.2 kg/m2), blood pressure (153.9/91.5 mmHg) and the proportions of women (53.6%) and treatment naïve patients (72.7%). After randomization, in the R and E groups combined, blood pressure dropped by 18.2/10.1 mmHg, 19.4/11.2 mmHg, 22.4/12.2 mmHg and 25.8/15.2 mmHg at weeks two (n = 122), four (n = 109), eight (n = 57), and 12 (n = 49), respectively. The control rate was >65% already at two weeks. At 12 weeks, 12 patients (24.5%) had progressed to the higher dose of R or E and/or had α-methyldopa added. Cohort analyses of 49 patients up to 12 weeks were confirmatory. Only two patients dropped out of the study. Conclusions NOAAH (NCT01030458) demonstrated that blood pressure control can be achieved fast in Black patients born and living in Africa with a simple regimen consisting of a single-pill combination of two antihypertensive agents. NOAAH proves that randomized clinical trials of cardiovascular drugs in the indigenous populations of sub-Saharan Africa are feasible.

Published
2012
Full Text
View/download PDF

14. A community-based study of hypertension and cardio-metabolic syndrome in semi-urban and rural communities in Nigeria

Author

Onodugo Obinna D, Ijoma Chinwuba K, and Ulasi Ifeoma I

Subjects
Public aspects of medicine, RA1-1270
Abstract

Abstract Background The prevalence of cardio-metabolic syndrome (CMS) is increasing worldwide. In people of African descent, there is higher prevalence of hypertension and complications than other races. Bearing in mind these facts, we looked at the CMS in the general population and the population with hypertension. Using the new International Diabetes Federation (IDF) definitions of CMS, we studied its prevalence in semi-urban and rural communities in South-east Nigeria in relation to hypertension. Method This is a cross sectional population based study involving 1458 adults aged from 25 to 64 years. Diagnosis of CMS was based on the new IDF criteria using the anthropometric measurements for Europids as there is none yet for blacks. Hypertension was defined according to the WHO/ISH criteria. Results The overall prevalence of CMS was 18.0% in the semi-urban community as against 10.0% in the rural community increasing to 34.7% and 24.7% respectively in the population with hypertension. The prevalence of co-morbidities - hyperglycaemia, abdominal obesity, and hypertriglceridaemia were 13.9%, 41.1% and 23.9% while in the hypertensive populations they were 21.2%, 55.0% and 31.3% in the general population in both communities combined. Except for low HDL cholesterol, every other co-morbidity was higher in hypertensive population than the general population. Conclusion The high prevalence of CMS in the semi-urban population especially for the population with hypertension underscores the double burden of disease in developing countries. The lesson is while infections and infestations are being tackled in these countries the non-communicable diseases should not be neglected.

Published
2010
Full Text
View/download PDF

15. Heart rate variability on antihypertensive drugs in black patients living in sub-Saharan Africa

Author

Osakwe, Chukwunomso E, Jacobs, Lotte, Anisiuba, Benedict C, Ndiaye, Mouhamado B, Lemogoum, Daniel, Ijoma, Chinwuba K, Kamdem, Marius M, Thijs, Lutgarde, Boombhi, Hilaire J, Kaptue, Joseph, Kolo, Philip M, Mipinda, Jean B, Odili, Augustine N, Ezeala-Adikaibe, Birinus, Kingue, Samuel, Omotoso, Babatunde A, Ba, Serigne A, Ulasi, Ifeoma I, M'buyamba-Kabangu, Jean-Rene, Staessen, Jan A, On behalf of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients Trial (NOAAH) Investigators, Epidemiologie, and RS: CARIM - R3 - Vascular biology

Subjects
Male, sub-Saharan Africa, medicine.medical_specialty, Cohort Studies, Hydrochlorothiazide, Heart Rate, Internal medicine, Heart rate, Internal Medicine, medicine, Heart rate variability, Humans, Amlodipine, Antihypertensive drugs, Africa South of the Sahara, Antihypertensive Agents, Traditional medicine, business.industry, heart rate variability, General Medicine, Middle Aged, medicine.disease, blacks, randomized clinical trial, 3. Good health, Blood pressure, Valsartan, Bisoprolol, Hypertension, Cardiology, Arterial stiffness, Original Article, Female, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract

Background. Compared with Caucasians, African Americans have lower heart rate variability (HRV) in the high-frequency domain, but there are no studies in Blacks born and living in Africa. Methods. In the Newer versus Older Antihypertensive agents in African Hypertensive patients trial (NCT01030458), patients (30-69 years) with uncomplicated hypertension (140-179/90-109 mmHg) were randomized to single-pill combinations of bisoprolol/hydrochlorothiazide (R) or amlodipine/valsartan (E). 72 R and 84 E patients underwent 5-min ECG recordings at randomization and 8, 16 and 24 weeks. HRV was determined by fast Fourier transform and autoregressive modelling. Results. Heart rate decreased by 9.5 beats/min in R patients with no change in E patients (- 2.2 beats/min). R patients had reduced total (- 0.13 ms²; p = 0.0038) and low-frequency power (- 3.6 nu; p = 0.057), higher high-frequency (+ 3.3 nu; p = 0.050) and a reduced low- to high-frequency ratio (- 0.08; p = 0.040). With adjustment for heart rate, these differences disappeared, except for the reduced low-frequency power in the R group (- 4.67 nu; p = 0.02). Analyses confined to 39 R and 47 E patients with HRV measurements at all visits or based on autoregressive modelling were confirmatory. Conclusion. In native Black African patients, antihypertensive drugs modulate HRV, an index of autonomous nervous tone. However, these effects were mediated by changes in heart rate except for low-frequency variability, which was reduced on beta blockade independent of heart rate. peerreview_statement: The publishing and review policy for this title is described in its Aims & Scope. aims_and_scope_url: http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=iblo20 ispartof: Blood Pressure vol:23 issue:3 pages:174-80 ispartof: location:England status: published

Published
2014

16. Cardiovascular disease risk factors in a Nigerian population with impaired fasting blood glucose level and diabetes mellitus

Author

Oguoma, Victor M., Nwose, Ezekiel U., Ulasi, Ifeoma I., Akintunde, Adeseye A., Chukwukelu, Ekene E., Bwititi, Phillip T., Richards, Ross S., Skinner, Timothy C., Oguoma, Victor M., Nwose, Ezekiel U., Ulasi, Ifeoma I., Akintunde, Adeseye A., Chukwukelu, Ekene E., Bwititi, Phillip T., Richards, Ross S., and Skinner, Timothy C.

Abstract

BackgroundDiabetes is a risk factor for cardiovascular diseases (CVDs) and there are reports of increasing prevalence of prediabetes in Nigeria. This study therefore characterised CVDs risk factors in subjects with impaired fasting glucose (IFG) and diabetes. MethodsData from 4 population-based cross-sectional studies on 2447 apparently healthy individuals from 18 - 89 years were analysed. Anthropometric, blood pressure and biochemical parameters were collected and classified. Individuals with IFG (prediabetes) and diabetes were merged each for positive cases of dyslipidaemia, high blood pressure (HBP) or obesity. Optimal Discriminant and Hierarchical Optimal Classification Tree Analysis (HO-CTA) were employed. ResultsOverall prevalence of IFG and diabetes were 5.8% (CI: 4.9 – 6.7%) and 3.1% (CI: 2.4 – 3.8%), respectively. IFG co-morbidity with dyslipidaemia (5.0%; CI: 4.1 – 5.8%) was the highest followed by overweight/obese (3.1%; CI: 2.5 – 3.8%) and HBP (1.8%; CI: 1.3 – 2.4%). The predicted age of IFG or diabetes and their co-morbidity with other CVD risk factors were between 40 – 45 years. Elevated blood level of total cholesterol was the most predictive co-morbid risk factor among IFG and diabetes subjects. Hypertriglyceridaemia was an important risk factor among IFG-normocholesterolaemic-overweight/obese individuals. ConclusionThe higher prevalence of co-morbidity of CVD risk factors with IFG than in diabetes plus the similar age of co-morbidity between IFG and diabetes highlights the need for risk assessment models for prediabetes and education of individuals at risk about factors that mitigate development of diabetes and CVDs.

Published
2017

23. Central haemodynamics reveal significant potential for prevention in Black hypertensive patients born and living in sub-Saharan Africa

Author

Ezeala-Adikaibe, Birinus, primary, Liu, Yan-Ping, primary, Lemogoum, Daniel, primary, Anisiuba, Benedict C., primary, Kamdem, Marius K., primary, Kaptue, Joseph, primary, Ijoma, Chinwuba K., primary, Thijs, Lutgarde, primary, Odili, Augustine N., primary, Asayama, Kei, primary, Staessen, Jan A., primary, M’Buyamba-Kabangu, Jean-René, primary, and Ulasi, Ifeoma I., primary

Published
2011
Full Text
View/download PDF

27. ENLARGED HEART FOUND IN NIGERIANS REPORTING WITH CHRONIC KIDNEY FAILURE.

Author

Ulasi, Ifeoma I., Arodiwe, Ejikeme B., and Ijoma, Chinwuba K.

Subjects
KIDNEY diseases, HEART dilatation, HEART diseases, HEART size, MEDICAL research
Abstract

The article highlights a study which focused on the prevalence of kidney disease and heart enlargement in Nigeria. According to the study, a strong link between long-standing kidney disease and heart enlargement does exist. The researchers recommend that early detection and treatment methods be followed aggressively as a preventive measure.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results